Recent Advances in CAR-Based Solid Tumor Immunotherapy
Cells · 11.06.2023 · 12 (12) · 1606
DOI: 10.3390/cells12121606 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cells, online erschienen am 11.06.2023. Verfasst von Min Hwa Shin und 6 weiteren Autor:innen. Beteiligte Einrichtung: Immune Research Institute, Seegene Medical Foundation, Seoul 04805, Republic of Korea. Hauptthemen laut MEDLINE: Receptors, Chimeric Antigen, Neoplasms. Die Arbeit wurde bisher 84-mal zitiert (Crossref) und nennt 135 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Adoptive cell therapy using chimeric antigen receptor (CAR) technology is one of the most advanced engineering platforms for cancer immunotherapy. CAR-T cells have shown remarkable efficacy in the treatment of hematological malignancies. However, their limitations in solid tumors include an immunosuppressive tumor microenvironment (TME), insufficient tumor infiltration, toxicity, and the absence of tumor-specific antigens. Although recent advances in CAR-T cell design—such as the incorporation of co-stimulatory domains and the development of armored CAR-T cells—have shown promising results in treating solid tumors, there are still challenges that need to be addressed. To overcome these limitations, other immune cells, such as natural killer (NK) cells and macrophages (M), have been developed as attractive options for efficient cancer immunotherapy of solid tumors. CAR-NK cells exhibit substantial clinical improvements with "off-the-shelf" availability and low toxicity. CAR-M cells have promising therapeutic potential because macrophages can infiltrate the TME of solid tumors. Here, we review the recent advances and future perspectives associated with engineered immune cell-based cancer immunotherapies for solid tumors. We also summarize ongoing clinical trials investigating the safety and efficacy of engineered immune cells, such as CAR-T, CAR-NK, and CAR-M, for targeting solid tumors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Immune Research Institute, Seegene Medical Foundation, Seoul 04805, Republic of Korea.
- Department of Diagnostic Immunology, Seegene Medical Foundation, Seoul 04805, Republic of Korea.
ORCID-Profile: Min Hwa Shin, Dohsik Minn
Zitieren
APA
Shin, M. H., Oh, E., Kim, Y., Nam, D. H., Jeon, S. Y., Yu, J. H., & Minn, D. (2023). Recent Advances in CAR-Based Solid Tumor Immunotherapy. Cells, 12(12), 1606. https://doi.org/10.3390/cells12121606
Vancouver
Shin MH, Oh E, Kim Y, Nam DH, Jeon SY, Yu JH, et al. Recent Advances in CAR-Based Solid Tumor Immunotherapy. Cells. 2023;12(12):1606. doi:10.3390/cells12121606
BibTeX
@article{Shin2023,
author = {Shin, Min Hwa and Oh, Eunha and Kim, Yunjeong and Nam, Dae-Hwan and Jeon, So Young and Yu, Jin Hyuk and Minn, Dohsik},
title = {Recent Advances in CAR-Based Solid Tumor Immunotherapy},
journal = {Cells},
year = {2023},
volume = {12},
number = {12},
pages = {1606},
doi = {10.3390/cells12121606}
}
EUVIMED